Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

Completed · Phase 3 · Has a placebo group

Conditions studied: Cystic Fibrosis

In brief

Study 110 is a Phase 3, multicenter study in subjects aged 6 years and older with cystic fibrosis (CF) who are homozygous for the F508del-CF transmembrane conductance regulator (CFTR) mutation and who participated in Study 109 (NCT02514473) or Study 011B (NCT01897233). Study 110 is designed to evaluate the safety and efficacy of long term treatment of lumacaftor in combination with ivacaftor.

Key facts

Study ID

NCT02544451

Run by

Vertex Pharmaceuticals Incorporated

People needed

246

Starts

2015-08-01

Expected to finish

2020-04-01

Last updated by the study team

2021-05-24

Who can join

Age: 6 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects entering the Treatment Cohort must meet both of the following criteria:
• Completed study visits up to Week 24 of Study 109 or Week 26 of Study 011B and did not permanently discontinue treatment
• Willing to remain on a stable CF medication through the Safety Follow-up Visit.
• Subjects entering the Observational Cohort must meet 1 of the following criteria:
• Completed 24 weeks of study drug treatment in Study 109 or completed 24 weeks of study drug treatment and the Week 26 Safety Follow up in Study 011B.
• Received at least 4 weeks of study drug and completed visits up to Week 24 of Study 109 or Week 26 of Study 011B.
• Exclusion Criteria (Treatment Cohort Only):
• History of any comorbidity or laboratory abnormality that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject (e.g., cirrhosis with portal hypertension).
• Pregnant and nursing females.
• Sexually active subjects of reproductive potential who are not willing to follow the contraception requirements.
• History of drug intolerance in the prior study that would pose an additional risk to the subject in the opinion of investigator
• History of poor compliance with study drug and/or procedure in the previous study as deemed by the investigator.
• Participation in an investigational drug trial (including studies investigating lumacaftor and/or ivacaftor).

Where it is running

• Study site — Tucson, Arizona, United States
• Study site — Long Beach, California, United States
• Study site — Palo Alto, California, United States
• Study site — Aurora, Colorado, United States
• Study site — Wilmington, Delaware, United States
• Study site — Jacksonville, Florida, United States
• Study site — Orlando, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Chicago, Illinois, United States
• Study site — Indianapolis, Indiana, United States
• Study site — Iowa City, Iowa, United States
• Study site — Boston, Massachusetts, United States
• Study site — Minneapolis, Minnesota, United States
• Study site — Kansas City, Missouri, United States
• Study site — St Louis, Missouri, United States
• Study site — Omaha, Nebraska, United States
• Study site — Lebanon, New Hampshire, United States
• Study site — Buffalo, New York, United States
• Study site — Syracuse, New York, United States
• Study site — Chapel Hill, North Carolina, United States
• Study site — Cincinnati, Ohio, United States
• Study site — Cleveland, Ohio, United States
• Study site — Dayton, Ohio, United States
• Study site — Portland, Oregon, United States
• Study site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.